MLL
PRQR icon

Moody Lynn & Lieberson’s ProQR Therapeutics PRQR Stock Holding History

Moody Lynn & Lieberson’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46.5K Hold
25,000
– – ﹤0.01% 262
2026
Q1 		$40.5K Hold
25,000
– – ﹤0.01% 249
2025
Q4 		$50.5K Buy
+25,000
New +$58.4K ﹤0.01% 264

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Moody Lynn & Lieberson's PRQR Position: Q2 2026 in Review

Moody Lynn & Lieberson held its ProQR Therapeutics (PRQR) position steady in Q2 2026 at 25,000 shares worth $46.5K. The position accounts for ﹤0.01% of the portfolio, ranked #262.

Moody Lynn & Lieberson first reported a position in PRQR in Q4 2025 and has held it in 3 quarters since. The position peaked at $50.5K in Q4 2025. 70 funds tracked by Wall St. Rank hold PRQR as of Q2 2026.

  • Moody Lynn & Lieberson held 25,000 shares of ProQR Therapeutics worth $46.5K as of Q2 2026.
  • Moody Lynn & Lieberson left its ProQR Therapeutics share count unchanged in Q2 2026.
  • ProQR Therapeutics made up ﹤0.01% of Moody Lynn & Lieberson's portfolio in Q2 2026, its #262 holding.
  • Moody Lynn & Lieberson first reported a position in ProQR Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Moody Lynn & Lieberson's ProQR Therapeutics position peaked at $50.5K in Q4 2025.
  • 70 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2026.

Based on Moody Lynn & Lieberson's 13F filing for Q2 2026, filed 20 Jul 2026.